Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Abstract The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM). This is a multi-institutional retrospective cohort study and included all consecutive patients that received at lea...

Full description

Bibliographic Details
Main Authors: Meera Mohan, Jorge Monge, Nishi Shah, Danny Luan, Mark Forsberg, Vineel Bhatlapenumarthi, Metodi Balev, Anannya Patwari, Heloise Cheruvalath, Divaya Bhutani, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Samer Al-Hadidi, Dennis Cooper, Suzanne Lentzsch, Frits van Rhee, Anita D’Souza, Aniko Szabo, Carolina Schinke, Rajshekhar Chakraborty
Format: Article
Language:English
Published: Nature Publishing Group 2024-03-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-024-01003-z

Internet

https://doi.org/10.1038/s41408-024-01003-z

Similar Items